WuXi Biologics (Cayman) (FRA:1FW2) EV-to-EBIT : 10.44 (As of Apr. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, WuXi Biologics (Cayman)'s Enterprise Value is €5,822 Mil. WuXi Biologics (Cayman)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €558 Mil. Therefore, WuXi Biologics (Cayman)'s EV-to-EBIT for today is 10.44.

The historical rank and industry rank for WuXi Biologics (Cayman)'s EV-to-EBIT or its related term are showing as below:

FRA:1FW2' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.54 Med: 123.95 Max: 281.77
Current: 10.32

During the past 10 years, the highest EV-to-EBIT of WuXi Biologics (Cayman) was 281.77. The lowest was 8.54. And the median was 123.95.

FRA:1FW2's EV-to-EBIT is ranked worse than
52.6% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs FRA:1FW2: 10.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. WuXi Biologics (Cayman)'s Enterprise Value for the quarter that ended in Jun. 2023 was €18,259 Mil. WuXi Biologics (Cayman)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €558 Mil. WuXi Biologics (Cayman)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 3.05%.

WuXi Biologics (Cayman) EV-to-EBIT Historical Data

The historical data trend for WuXi Biologics (Cayman)'s EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) EV-to-EBIT Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

96.24

172.60

78.25

41.19

25.02

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial													78.25	-	41.19	-	-

Competitive Comparison of WuXi Biologics (Cayman)'s EV-to-EBIT

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman)'s EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s EV-to-EBIT falls into.

WuXi Biologics (Cayman) EV-to-EBIT Calculation

WuXi Biologics (Cayman)'s EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	5821.927	/	557.58
	=	10.44

WuXi Biologics (Cayman)'s current Enterprise Value is €5,822 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €558 Mil.

WuXi Biologics (Cayman) (FRA:1FW2) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

WuXi Biologics (Cayman)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	557.58	/	18259.43598
	=	3.05 %

WuXi Biologics (Cayman)'s Enterprise Value for the quarter that ended in Jun. 2023 was €18,259 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €558 Mil.

WuXi Biologics (Cayman) EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines